WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006079916) THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/079916    International Application No.:    PCT/IB2006/000172
Publication Date: 03.08.2006 International Filing Date: 17.01.2006
Chapter 2 Demand Filed:    18.04.2006    
IPC:
C07D 495/04 (2006.01), A61P 7/02 (2006.01), A61K 31/519 (2006.01)
Applicants: PHARMACIA & UPJOHN COMPANY LLC [US/US]; 7000 Portage Road, Kalamazoo, MI 49001-0199 (US) (For All Designated States Except US).
ENNIS, Michael, Dalton [US/US]; (US) (For US Only).
KORTUM, Steven, Wade [US/US]; (US) (For US Only).
RAHMAN, Hayat [US/US]; (US) (For US Only).
SCHWEITZER, Barbara, Ann [US/US]; (US) (For US Only).
TENBRINK, Ruth, Elizabeth [US/US]; (US) (For US Only)
Inventors: ENNIS, Michael, Dalton; (US).
KORTUM, Steven, Wade; (US).
RAHMAN, Hayat; (US).
SCHWEITZER, Barbara, Ann; (US).
TENBRINK, Ruth, Elizabeth; (US)
Agent: FULLER, Grover, F., Jr.; Pfizer Inc., 150 East 42nd Street, New York, NY 10017-5612 (US)
Priority Data:
60/647,340 26.01.2005 US
60/659,337 07.03.2005 US
Title (EN) THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION
(FR) COMPOSES DE THIENO [2,3-D] PYRIMIDINE UTILISES COMME INHIBITEURS D'AGREGATION DE PLAQUETTES INDUITS PAR ADP
Abstract: front page image
(EN)Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
(FR)L'invention concerne des composés et des sels de ceux-ci pharmaceutiquement acceptables. Ces composés sont représentés par la formule (I) dans laquelle A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5 et R6 sont tels que définis dans la description de l'invention. L'invention concerne également des compositions pharmaceutiques correspondantes, des méthodes de traitement, des méthodes de synthèse et des intermédiaires.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)